Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 878

Related Citations for PubMed (Select 15694232)

1.

Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.

Akhondzadeh S, Safarcherati A, Amini H.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):253-9. Epub 2004 Dec 28.

PMID:
15694232
2.

Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial.

Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, Raisi F, Kamalipour A.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):1007-12.

PMID:
14499318
3.

A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.

Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, Noorbala AA, Ahmadi-Abhari SA, Hajiazim M, Abbasi SH, Akhondzadeh S.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):726-32. Epub 2007 Nov 23.

PMID:
18096287
4.

Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia.

Akhondzadeh S, Mojtahedzadeh V, Mirsepassi GR, Moin M, Amini-Nooshabadi H, Kamalipour A.

J Clin Pharm Ther. 2002 Dec;27(6):453-9.

PMID:
12472985
5.

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.

Hum Psychopharmacol. 2008 Mar;23(2):79-86.

PMID:
17972359
6.

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1879-83. doi: 10.1016/j.pnpbp.2008.08.020. Epub 2008 Sep 4.

PMID:
18801405
7.

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.

Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B.

Schizophr Res. 2007 Feb;90(1-3):179-85. Epub 2007 Jan 8.

PMID:
17208413
8.

A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia.

Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR.

J Clin Psychiatry. 2005 Feb;66(2):213-9.

PMID:
15705007
9.
10.

Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia.

Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H.

J Clin Pharm Ther. 1999 Oct;24(5):369-74.

PMID:
10583700
11.

A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.

Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY.

J Clin Psychiatry. 2001 Nov;62(11):878-83.

PMID:
11775047
12.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
13.
14.

Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study.

Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, Davari-Ashtiani R.

J Clin Pharm Ther. 1999 Feb;24(1):49-52.

PMID:
10319907
15.

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y.

CNS Drugs. 2009;23(7):615-25. doi: 10.2165/00023210-200923070-00006.

PMID:
19552488
16.

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.

Kramer MS, Last B, Getson A, Reines SA.

Arch Gen Psychiatry. 1997 Jun;54(6):567-72. Erratum in: Arch Gen Psychiatry 1997 Dec;54(12):1080.

PMID:
9193198
17.

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.

Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlösser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W.

Int J Neuropsychopharmacol. 2008 Nov;11(7):985-97. doi: 10.1017/S1461145708008791. Epub 2008 May 9.

PMID:
18466670
19.

Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.

Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA.

Psychopharmacology (Berl). 2011 Feb;213(4):809-15. doi: 10.1007/s00213-010-2044-z. Epub 2010 Oct 15.

PMID:
20949350
20.

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.

Freeman HL.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S11-7. Review.

PMID:
9218163
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk